Corsair Gaming Inc vs Twist Bioscience Corp — how do they compare? Corsair Gaming Inc trades at $13.63 (market cap $1.42B), while Twist Bioscience Corp trades at $159.78 (market cap $10.08B). The key difference: Twist Bioscience Corp is far larger — about 7.1× Corsair Gaming Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, Twist Bioscience Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Corsair Gaming Inc for 25 Days and Twist Bioscience Corp for 27 Days on average.
| CRSR | TWST | |
|---|---|---|
Market Cap | $1.42B | $10.08B |
Volume | 1,160,938 | 4,229,037 |
Sector | Technology | Health |
52-Week High | $14.35 | $205.00 |
52-Week Low | $4.58 | $25.45 |
Typical Hold Time | 25 Days | 27 Days |
Enterprise Value | $1.41B | $10.01B |
Signals from Pluang's Aura AI — not financial advice
CRSR trades at $13.09, down 3.68% on the day, with a bullish technical signal from moving averages and recent earnings beats. The company reported Q2 2026 EPS of $0.23, beating estimates of $0.07, and raised full-year guidance. Revenue for 2025 was $1.47B, with a net income margin of 2.53% in 2026 projections. Analyst consensus is a $12.40 price target with a mix of Buy (36%) and Hold (64%) ratings. Recent news includes product launches like the VOXARA microphone and strategic acquisitions.
Outlook is cautiously optimistic due to strong earnings performance and new product initiatives, but risks include competitive pressures in gaming hardware and volatile cash flow trends. The stock's valuation at a P/E of 42.23 may limit near-term upside unless profit growth accelerates. Institutional interest is positive, with Canada Pension Plan adding a position in Q3 2026.
TWST trades at $152.05, down 2.31% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported Q2 2026 EPS of -$0.56, missing expectations, continuing a trend of losses despite revenue growth to $376.57M in 2025. Recent news highlights a partnership with Lilly TuneLab for AI-driven drug discovery, driving investor optimism.
Outlook remains speculative with high valuation multiples (P/S 21.5, P/B 22.62) and persistent losses, but analyst consensus is bullish (73% buy ratings) with a $145.20 price target. Key risks include cash burn, competitive pressures, and reliance on AI-driven growth catalysts for profitability.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →